Works matching IS 11732563 AND DT 2017 AND VI 37 AND IP 2
Results: 9
Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 2, p. 175, doi. 10.1007/s40261-016-0471-2
- By:
- Publication type:
- Article
Relationship between Adverse Gastric Reactions and the Timing of Enteric-Coated Aspirin Administration.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 2, p. 187, doi. 10.1007/s40261-016-0474-z
- By:
- Publication type:
- Article
Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 2, p. 155, doi. 10.1007/s40261-016-0465-0
- By:
- Publication type:
- Article
Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 2, p. 167, doi. 10.1007/s40261-016-0469-9
- By:
- Publication type:
- Article
Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 2, p. 135, doi. 10.1007/s40261-016-0475-y
- By:
- Publication type:
- Article
Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 2, p. 105, doi. 10.1007/s40261-016-0472-1
- By:
- Publication type:
- Article
Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 2, p. 207, doi. 10.1007/s40261-016-0479-7
- By:
- Publication type:
- Article
Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 2, p. 195, doi. 10.1007/s40261-016-0476-x
- By:
- Publication type:
- Article
Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 2, p. 121, doi. 10.1007/s40261-016-0460-5
- By:
- Publication type:
- Article